Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study

Schizophrenia Research

Volumn 127, Issue 1-3, 2011, Pages 93-99

  Muscatello, Maria Rosaria A ^a   Bruno, Antonio ^a   Pandolfo, Gianluca ^a   Micò, Umberto ^a   Scimeca, Giuseppe ^a   Di Nardo, Floriana ^a   Santoro, Vincenza ^b   Spina, Edoardo ^a,b   Zoccali, Rocco A ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Aripiprazole; Augmentation; Clozapine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; LORAZEPAM; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; BRAIN FUNCTION; BREATHING RATE; CLINICAL ARTICLE; COGNITION; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART DISEASE; HEART RATE; HUMAN; HYPERSALIVATION; INSOMNIA; LIPID METABOLISM; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; TEMPERATURE;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TIME FACTORS;

EID: 79952360373     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.12.011     Document Type: Article

References (62)

1. Addington D., Addington J., Maticka- Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry 1993, 33(Suppl. 22):39-44.
2. Andreasen N. Scale for the assessment of Negative Symptoms (SANS). University of Iowa, Iowa 1983.
3. Andreasen N. Scale for the assessment of Positive Symptoms (SAPS). University of Iowa, Iowa 1984.
4. Ashton A.K. Aripiprazole augmentation of clozapine in refractory schizophrenia. Psychiatry 2005, 2:18-19.
5. Bartels C., Wegrzyn M., Wiedl A., Ackermann V., Ehrenreich H. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci. 2010, 11:118. http://www.biomedcentral.com/1471-2202/11/118.
6. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33(4):1013-1022.
7. Chakos M., Lieberman J., Hoffman E. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 2001, 158:518-526.
8. Chang J.S., Ahn Y.M., Park H.J., Lee K.Y., Kim S.H., Kang U.G., Kim Y.S. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2008, 69(5):720-731.
9. Chemerinski E., Reichenberg A., Kirkpatrick B., Bowie C.R., Harvey P.D. Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-years cognitive and functional status. Schizophr. Res. 2006, 85(1-3):12-19.
10. Cipriani A., Boso M., Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia (Review). Cochrane Database Syst. Rev. 2010, 8(3):CD006324.
11. Clarke L.A., Lindenmayer J.P., Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J. Clin. Psychiatry 2006, 67(4):675-676.
12. Conley R.R., Kelly D.L. Management of treatment-resistant schizophrenia. Biol. Psychiatry 2001, 50:898-911.
13. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Does antispychotic polipharmacy increase the risk for metabolic syndrome?. Schizophr. Res. 2007, 89(1-3):91-100.
14. Davies M., Sheffler D., Roth B. Aripiprazole: a novel atypical antipsychotic drug with a unique robust pharmacology. CNS Drugs Rev. 2004, 10:317-336.
15. De Quardo J.R. Increased efficacy with addition of clozapine to aripiprazole: alternative explanations. J. Clin. Psychiatry 2005, 66:396.
16. English S., Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1386-1392.
17. Fleischhacker W.W., Heikkinen M.E., Olié J.-P., Landsberg W., Dewaele P., McQuade R.D., Loze J.-Y., Hennicken D., Kerselaers W. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 2010, 13:1115-1125.
18. Genç Y., Taner E., Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv. Ther. 2007, 24(1):1-13.
19. Glick I.D., Zaninelli R., Hsu C., Young F.K., Weiss L., Gunay I., Kumar V. Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. J. Clin. Psychiatry 2004, 65(5):679-685.
20. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 2007, 64:1115-1122.
21. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-326.
22. Heaton R., Chelune G., Talley J., Kay G., Curtis G. Wisconsin Card Sorting Test manual. Psychological Resources, Odessa, FL 1993.
23. Henderson D.C., Kunkel L., Nguyen D.D., Borba C.P., Daley T.B., Louie P.M., Freudenreich O., Cather C., Evins A.E., Goff D.C. An exploratory open label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr. Scand. 2006, 113:142-147.
24. Hennen J., Baldessarini R.J. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr. Res. 2005, 73:139-145.
25. Josiassen R.C., Joseph A., Kohegyi E., Stokes S., Dadvand M., Paing W.W., Shaughnessy R.A. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 2005, 162(1):130-136.
26. Kane J., Honigfeld G., Singer J. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
27. Karunakaran K., Tungaraza T.E., Harborne G. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?. J. Psychopharmacol. 2007, 21(4):453-456.
28. Kern R.S., Green M.F., Cornblatt B.A., Owen J.R., McQuade R.D., Carson W.H., Ali M., Marcus R. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacol. Berl 2006, 187:312-320.
29. Kessler R.M. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?. Am. J. Psychiatry 2007, 164:1310-1312.
30. Kitamura T., Suga R. Depressive and negative symptoms in major psychiatric disorders. Compr. Psychiatry 2001, 32(1):88-94.
31. Kremer I., Vass A., Gorelik I., Bar G., Blanaru M., Javitt D.C., Heresco-Levy U. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiatry 2004, 56:441-446.
32. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br. J. Psychiatry 2005, 187:366-371.
33. Li Z., Ichikawa J., Dai J., Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 2004, 493(1-3):75-83.
34. Lim S., Pralea C., Schnitt J., Bowers M.B., Cooper C. Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J. Clin. Psychiatry 2004, 65(9):1284-1285.
35. Meltzer H., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1159-1172.
36. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003, 60:82-91.
37. Mitsonis C.I., Dimopoulos N.P., Mitropoulos P.A., Kararizou E.G., Katsa A.N., Tsakiris F.E., Katsanou M.N.E. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:373-377.
38. Mucci A., Piegari G., Galderisi S. Cognitive-enhancing effects of aripiprazole: a case report. Clin. Pract. Epidemol. Ment. Health 2008, 4:24.
39. Munro J., Matthiasson P., Osborne S., Travis M., Purcell S., Cobb A.M., Launer M., Beer M.D., Kerwin R. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiat. Scand. 2004, 110:292-298.
40. Naber D., Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 28:1213-1219.
41. National Institute for Clinical Excellence. Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care. NICE Guidelines 2002.
42. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Report 1962, 10:799-812.
43. Remington G., Saha A., Chong S., Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005, 19(10):843-872.
44. Riedel M., Schennach-Wolff R., Musil R., Dehning S., Cerovecki A., Opgen-Rhein M., Matz J., Seemüller F., Obermeier M., Engel R.R., Müller N., Muller H.-J., Spellmann I. Neurocognition and its influencing factors in the treatment of schizophrenia - effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum. Psychopharmacol. Clin. Exp. 2010, 25:116-125.
45. Riedel M., Spellmann I., Schennach-Wolff R., Musil R., Dehning S., Cerovecki A., Opgen-Rhein M., Matz J., Seemüller F., Obermeier M., Severus E., Engel R.R., Müller N., MOdouble acuteller H.-J. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry 2010, 43:50-57.
46. Rocha F.L., Hara C. Benefits of combining aripiprazole to clozapine: three case reports. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1167-1169.
47. Sernyak M.J., Rosenheck R. Clinicians' reasons for antipsychotic co-prescribing. J. Clin. Psychiatry 2004, 65:1597-1600.
48. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400-1411.
49. Shiloh R., Zemishlany Z., Aizenberg D., Radwan M., Schwartz B., Dorfman-Etrog P., Modai I., Khaikin M., Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br. J. Psychiatry 1997, 171:569-573. single-blind randomized study. Adv. Ther. 24 (1), 1-13.
50. Spina E., de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxicol. 2007, 100:4-22.
51. Spreen O., Benton A.L. Neurosensory Center Comprehensive Examination For Aphasia (NCCEA). University of Victoria Neuropsychology Laboratory, Victoria 1977.
52. Stoner S.C., Dahmen M.M., Berges A., Petry W.M. Augmentation with aripiprazole with low-dose clozapine. Pharmacotherapy 2007, 27(11):1599-1602.
53. Tamminga C.A., Holcomb H.H. Phenotype of schizophrenia: a review and formulation. Mol. Psychiatry 2005, 10:27-39.
54. Tiihonen J., Hallikainen T., Ryynänen O.-P., Repo-Tiihonen E., Kotilainen I., Eronen M., Toivonen P., Wahlbeck K., Putkonen A. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry 2003, 54:1241-1248.
55. Tiihonen J., Wahlbeck K., Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2009, 109(1-3):10-14.
56. Trenerry M.R., Crosson B., DeBoe J., Leber W.R. Stroop Neuropsychological Screening Test. Psychological Assessment Resources, Inc., Odessa FL 1989.
57. Tuunainen A., Wahlbeck K., Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr. Res. 2002, 56:1-10.
58. Wahlbeck K., Cheine M.V., Essali A. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst. Rev. 2000, 2:CD000059.
59. Ziegenbein M., Wittmann G., Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia - a clinical observation. Clin. Drug Investig. 2006, 26(3):117-124.
60. Zink M., Kuwilsky A., Krumm B., Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J. Psychopharmacol. 2009, 23:305-314.
61. Zoccali R., Muscatello M.R., Bruno A., Cambria R., Micò U., Spina E., Meduri M. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr. Res. 2007, 93(1-3):109-116.
62. Zocchi A., Fabbri D., Heidbreder C.A. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci. Lett. 2005, 387(3):157-161.